GlassScriptPhysician profile
Amanda Burnette
NPI 1427546233
$2,350.37
in general payments reported to CMS, 2019-2025
25 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.80 · 2020: $15.29 · 2021: $103 · 2022: $245 · 2023: $587 · 2024: $582 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.89 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $385.73 | 2022-2025 | Vraylar, Viberzi, Linzess |
| Glaxosmithkline, LLC. | $216.22 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $177.09 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $141.30 | 2021-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $108.45 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.43 | 2022-2025 | |
| Dexcom, INC. | $86.66 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $81.81 | 2023-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.93 | 2023-2025 | Xifaxan, Trulance |
| Stryker Corporation | $60.39 | 2025 | Clottriever Bold Catheter |
| Xeris Pharmaceuticals, INC. | $59.34 | 2023 | Keveyis, Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $47.99 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.83 | 2021-2024 | |
| Abbott Laboratories | $32.66 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $29.69 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $23.83 | 2019-2021 | |
| Shield Therapeutics INC | $21.72 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $20.38 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $19.82 | 2025 | |
| Verona Pharma, INC. | $15.65 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $13.81 | 2022 | |
| Corcept Therapeutics | $13.68 | 2025 | Korlym |
| Exact Sciences Corporation | $13.65 | 2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $4.42 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Burnette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.